# Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia

> **NCT03571087** · PHASE3 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 374 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HL140 5/10
- **DRUG:** HL140 10/10
- **DRUG:** HL140 20/10
- **DRUG:** Rosuvastatin 5mg → HL140 5/10
- **DRUG:** Rosuvastatin 10mg → HL140 10/10
- **DRUG:** Rosuvastatin 20mg → HL140 20/10

## Key facts

- **NCT ID:** NCT03571087
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571087, "Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03571087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*